Effect of vitamin D supplementation on metabolic syndrome and atherosclerosis biomarkers in epilepsy: a randomized controlled trial
Medicinski Glasnik · 27.02.2026 · 23 (1) · 111-116
DOI: 10.17392/2062-23-01 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Medicinski Glasnik, online erschienen am 27.02.2026. Verfasst von Sri Handayani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Sriwijaya University, Palembang, Indonesia. Hauptthemen laut MEDLINE: Epilepsy, Vitamin D, Metabolic Syndrome, Atherosclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
<p><strong>Aim </strong>To analyze the effect of vitamin D administration on serum 25(OH)D levels and biomarkers of metabolic syndrome and atherosclerosis (homeostatic model assessment of insulin resistance [HOMA-IR], adiponectin, homocysteine, and high sensitivity C-reactive protein [hs-CRP]) in epilepsy patients receiving enzymatic antiseizure medications (ASMs).</p> <p><strong>Methods </strong>This double-blind, randomized, placebo-controlled trial randomized 40 adult epilepsy patients treated with enzymatic ASMs to receive vitamin D3 (2,000 IU/day) or placebo for 12 weeks. The primary outcome was the change in serum 25-hydroxyvitamin D (25[OH]D) levels. Secondary outcomes included changes in HOMA-IR, adiponectin, homocysteine, and hs-CRP. Data were analyzed using a per-protocol approach.</p> <p><strong>Results </strong>Thirty-four patients completed the study. Vitamin D supplementation yielded a significantly greater increase in serum 25(OH)D (10.67 ± 8.16 vs. –1.29 ± 3.96 ng/mL; p < 0.001) and adiponectin (1.38 ± 3.05 vs. 0.34 ± 1.89 µg/mL; p = 0.045), as well as a significantly greater reduction in hs-CRP (–6.74 ± 14.65 vs. 1.81 ± 7.75 mg/L; p = 0.041) compared with placebo. Conversely, no significant differences were observed between groups regarding the changes in HOMA-IR (–0.24 ± 3.71 vs. –0.14 ± 3.38; p = 0.940) or homocysteine (7.90 ± 1.79 vs. 8.15 ± 2.70 µmol/L; p = 0.290).</p> <p><strong>Conclusion </strong>Vitamin D supplementation (2,000 IU/day) effectively restores 25(OH)D levels and improves adiponectin and hs-CRP in epilepsy patients on enzymatic ASMs, suggesting a potential benefit for cardiovascular risk reduction. However, vitamin D alone did not prevent the rise in homocysteine, likely due to the concurrent cessation of B-vitamin supplementation.</p>
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Department, Sriwijaya University, Palembang, Indonesia.
- Biomedicine Division, Sriwijaya University, Palembang, Indonesia.
- Neurology Department, University of Indonesia, Depok, Indonesia.
- Division of Nephrology and Hypertension, Department of Internal Medicine, Sriwijaya University, Palembang, Indonesia.
- Department of Pharmacology, Sriwijaya University, Palembang, Indonesia.
- Sriwijaya University, Palembang, Indonesia.
Zitieren
APA
Handayani, S., Hafy, Z., Octaviana, F., Ali, Z., Parisa, N., Budikayanti, A., Agustini, D., & Partan, R. U. (2026). Effect of vitamin D supplementation on metabolic syndrome and atherosclerosis biomarkers in epilepsy: a randomized controlled trial. Medicinski Glasnik, 23(1), 111-116. https://doi.org/10.17392/2062-23-01
Vancouver
Handayani S, Hafy Z, Octaviana F, Ali Z, Parisa N, Budikayanti A, et al. Effect of vitamin D supplementation on metabolic syndrome and atherosclerosis biomarkers in epilepsy: a randomized controlled trial. Medicinski Glasnik. 2026;23(1):111-116. doi:10.17392/2062-23-01
BibTeX
@article{Handayani2026,
author = {Handayani, Sri and Hafy, Zen and Octaviana, Fitri and Ali, Zulkhair and Parisa, Nita and Budikayanti, Astri and Agustini, Dessy and Partan, Radiyati Umi},
title = {Effect of vitamin D supplementation on metabolic syndrome and atherosclerosis biomarkers in epilepsy: a randomized controlled trial},
journal = {Medicinski Glasnik},
year = {2026},
volume = {23},
number = {1},
pages = {111--116},
doi = {10.17392/2062-23-01}
}
EUVIMED